{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"176-848-176-887-073","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"176-848-176-887-073"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8906,"type":"PATENT","title":"Univ Pennsylvania Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":24238,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8221,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
administering to a subject in need thereof a cathepsin inhibitor in an effective amount for inhibiting viral entry wherein the enveloped virus is a filovirus and wherein the cathepsin inhibitor is selected from the group consisting of cathepsin-B inhibitor and cathepsin- L inhibitor, wherein the cathepsin inhibitor is not a lysosomotropic agent."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["A method for inhibiting infection by an enveloped virus in a subject, comprising administering to a subject in need thereof a cathepsin inhibitor in an effective amount for inhibiting viral entry wherein the enveloped virus is a filovirus and wherein the cathepsin inhibitor is one or more cathepsin-B or cathepsin-L inhibitors selected from a group consisting of epoxysuccinyl peptide derivatives selected from the group consisting of E-64, E-64a, E-64b, E-64c, E-64d, CA-074, CA-074 Me, CA-030, and CA-028, peptidyl aldehyde derivatives selected from the group consisting of leupeptin, antipain, chymostatin, Ac-LVK-CHO, Z-Phe-Tyr-CHO, Z-Phe-Tyr (OtBu)-COCHO.H2O, 1-Naphthalenesulfonyl-Ile-Trp-CHO, and Z-Phe-Leu-COCHO.H2O, peptidyl semicarbazone, peptidyl methylketone, peptidyl trifluoromethylketone derivatives selected from the group consisting of Biotin-Phe-Ala-fluoromethyl ketone, Z-Leu-Leu-Leu-fluoromethyl ketone minimum, Z-Phe-Phe-fluoromethyl ketone, N-Methoxysuccinyl-Phe-HOMO-Phe-fluoromethyl ketone, Z-Leu-Leu-Tyr-fluoromethyl ketone, Leupeptin trifluoroacetate, and ketone, bis(acylamino)ketone [1,3-Bis(CBZ-Leu-NH)-2-propanone, peptidyl diazomethanes, Z-Phe-Ala-CHN2, Z-Phe-Thr(OBz1)-CHN2, Z-Phe-Tyr (O-t-But)-CHN2, Z-Leu-Leu-Tyr-CHN2, peptidyl acyloxymethyl ketones, peptidyl methylsulfonium salts, peptidyl vinyl sulfones, peptidyl nitriles, 2-nitrobenzoic acid, azapeptides, azobenzenes, O-acylhydroxamates, Cystatins A, B, C, stefins, kininogens, Procathepsin B Fragment 26-50, and Procathepsin B Fragment 36-50."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the filovirus is an Ebola virus."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the filovirus is a Marburg virus."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the cathepsin inhibitor is administered orally."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the cathepsin inhibitor is administered intravenously."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein multiple doses of the cathepsin inhibitor are administered."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the cathepsin inhibitor is administered every 12 hours."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the cathepsin inhibitor is administered in combination with another protease inhibitor."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the subject is a human."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the subject is a non-human animal."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the cathepsin inhibitor is one or more selected from a group consisting of E-64, E-64d, CA-074, CA-074 Me, and leupeptin."],"number":12,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}